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ABSTRACT
Purpose and Experimental Design: The stem cell factor/
KIT receptor loop may represent a novel target for molec-
ular-based therapies of Ewing tumor. We analyzed the in
vitro impact of KIT blockade by imatinib in Ewing tumor
cell lines.
Results: KIT expression was detected in 4 of 4 Ewing
tumor cell lines and in 49 of 110 patient samples (44.5%) by
immunohistochemistry and/or Western blot analysis. KIT
expression was stronger in Ewing tumors showing EWS-
FLI1 nontype 1 fusions. Despite absence of c-kit mutations,
constitutive and ligand-inducible phosphorylation of KIT
was found in all tumor cell lines, indicating an active recep-
tor. Treatment with KIT tyrosine kinase inhibitor imatinib
(0.5–20 M) induced down-regulation of KIT phosphoryla-
tion and dose response inhibition of cell proliferation (IC50,
12–15 M). However, imatinib administered alone at doses
close to IC50 for growth inhibition (10 M) did not induce a
significant increase in apoptosis. We then analyzed if block-
ade of KIT loop through imatinib (10 M) was able to
increase the antitumor in vitro effect of doxorubicin (DXR)
and vincristine (VCR), drugs usually used in Ewing tumor
treatment. Addition of imatinib decreased in 15–20 and
15–36% of the proliferative rate of Ewing tumor cells ex-
posed to DXR and VCR, respectively, and increased in 15
and 30% of the apoptotic rate of Ewing tumor cells exposed
to the same drugs.
Conclusions: Inhibition of Ewing tumor cell prolifera-
tion by imatinib is mediated through blockade of KIT re-
ceptor signaling. Inhibition of KIT increases sensitivity of
these cells to DXR and VCR. This study supports a potential
role for imatinib in the treatment of Ewing tumor.
INTRODUCTION
Ewing tumor is a highly aggressive neoplasm preferentially
diagnosed in bone and soft tissues of children and young adults,
which show 5-year survival rates of only 50% despite the use of
multimodal therapeutic approaches (1). Since the early 1980s,
improved outcomes were reported with the inclusion of doxo-
rubicin (DXR), nearly every chemotherapy protocol for Ewing
tumor included at least doxorubicin and vincristine (VCR; Ref.
2). Growth of clinically detectable metastases, present in 30%
of patients at diagnosis, represents the most adverse prognostic
factor (2). Results are particularly unfavorable in patients with
metastases to bone and/or bone marrow; dose-intensive use of
the chemotherapy agents with established activity in Ewing
tumor is reaching its efficacy and toxicity limits in these par-
ticular cases (3). Search for new therapeutic targets and devel-
opment of novel therapeutic modalities are therefore needed for
treatment of these subsets of patients with Ewing tumor.
Ewing tumor is characterized by the presence of chimeric
proteins that fuse the NH2-terminal domain of the RNA-binding
protein EWS, with the DNA binding moiety of an ETS tran-
scription factor (FLI-1 in 90% of cases; Ref. 4–11). Extensive
experimental data exist that demonstrate the oncogenic potential
of EWS-ETS fusions (12, 13). Ewing tumor proliferation and
survival is also determined by autocrine and paracrine activation
of growth factor receptors and their ligands, including insulin-
like growth factor I, gastrin-releasing peptide, and their recep-
tors (14, 15). KIT and its ligand stem cell factor (SCF) represent
an additional example of an autocrine loop in Ewing tumor.
Stimulation with SCF induces tyrosine autophosphorylation of
KIT and of a number of mediators involved in the subsequent
intracellular signaling, including phosphatidylinositol 3-kinase,
and mitogen-activated protein kinase (MAPK; Ref. 16). Neo-
plastic transformation has been established via mutation of c-kit
gene, which results in ligand-independent activation of the re-
ceptor in a number of human tumors such as human mast cell
tumors (17, 18), chronic myelogenous leukemia (19), germ cell
tumors (20), and gastrointestinal stromal tumors (GISTs; Refs.
21–23). Overexpression of SCF and KIT has been demonstrated
in a number of malignancies (small cell lung carcinoma, ovarian
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carcinoma, breast carcinoma, and melanoma; Ref. 24) and in
Ewing tumor cell lines (25, 26). In most cases, the role of the
SCF/KIT loop in supporting the proliferation and/or survival of
these tumors has not been well established. Recent in vitro
studies suggest that SCF induces proliferation of Ewing tumor
cell lines and increases their metastatic potential (26) and show
that KIT blockade by high doses (20 M) of imatinib in serum-
deprived cells induces apoptosis (27).
Imatinib (Gleevec; Novartis Pharmaceuticals, Basel, Swit-
zerland) is a tyrosine-kinase inhibitor that selectively blocks
tyrosine phosphorylation of KIT and platelet-derived growth
factor receptors  and . Imatinib inhibits BCR-ABL kinase
activity in patients with chronic myelogenous leukemia (28, 29)
and is also active in patients with GISTs in which mutations of
the c-kit gene result in a constitutively activated receptor (30–
32). This compound may have clinical use in other neoplasms in
which KIT is involved in proliferative or antiapoptotic re-
sponses.
In the current study, two basic questions were addressed:
which is the expression and function of KIT receptor in Ewing
tumor samples and cell lines, and which is the effect of Imatinib
alone and in combination on proliferation and apoptosis of
Ewing tumor cells? Our results support a potential role of
imatinib in the treatment of this neoplasm.
MATERIALS AND METHODS
Cell Lines and Clinical Samples. SK-ES-1 (a gift from
Dr. Santiago Ramo´n y Cajal, Vall d’Hebron Hospital, Barce-
lona, Spain), with a type 2 EWS-FLI-1 fusion was routinely
cultured in McCoy’s medium (Biochrom KG) with 15% heat-
inactivated fetal serum (Life Technologies, Inc.). A673, ob-
tained from the European Collection of Animal Cell Cultures,
with a EWS-FLI-1 type 1 fusion was routinely cultured in
DMEM (Life Technologies, Inc.) with 10% heat-inactivated
fetal serum. TC-71, with a EWS-FLI-1 type 1 fusion, and
A4573, with a EWS-FLI-1 type 3 fusion (a gift from Dr. Samuel
Navarro, Universidad de Valencia, Spain), were cultured in
Iscove’s modified Dulbecco’s medium (Life Technologies, Inc.)
with 20% heat-inactivated fetal serum.
A total of 110 formalin-fixed, paraffin-embedded Ewing
tumor consecutive samples from 78 patients (49 males and 29
females; mean age at diagnosis 18 years) was available for
immunohistochemical study in our institution’s files. Snap-
frozen tissue was available in 42 samples; EWS-ETS transcript
determination was performed as reported elsewhere (33). The
study was approved by the Local Ethics Committee.
Expression Analysis (Reverse Transcription-PCR).
Total RNA was extracted from cell lines and Ewing tumor
clinical samples by using Ultraespec RNA (Biotecx Laborato-
ries, Inc.). cDNA was obtained by using 1 g of total RNA.
Conditions used for reverse transcription, c-kit and SCF ampli-
fication, and PCR primers were reported previously (34).
SCF and c-kit Sequencing. Sequencing of the whole
coding region of c-kit and SCF was performed in all Ewing
tumor cell lines and in four Ewing tumor clinical samples.
cDNA was amplified using Platinum TaqDNA polymerase high
fidelity (11304-011; Invitrogen) and previously reported prim-
ers (17). Purified PCR fragments were fully sequenced with
sense and antisense primers by fluorescence-based dideoxy ter-
minator cycle sequencing (Beckman Coulter, Fullerton, CA).
Data collection and analysis were performed on an automated
DNA sequencer (CEQ 2000XL DNA Analysis System; Beck-
man Coulter). GNNK/ receptor isoforms were previously
cloned in the plasmid vector pCR4-TOPO (Invitrogen) and then
sequenced with T3 and T7 primers as described above.
Western Blot and Immunoprecipitation Analysis. The
expression of KIT was determined by Western blotting in all
cell lines and in four Ewing tumor clinical samples. For protein
extraction, cells were scraped off the dish, pelleted, washed
twice in cold PBS, resuspended in radioimmunoprecipitation
assay buffer, incubated 30 min on ice, and then centrifuged at
13,000  g for 15 min at 4°C. Protein concentration for each
lysate was determined using the BCA Protein Assay Reagent
(Pierce). Proteins (50 g/lane) were resolved on 8% SDS-
PAGE, transferred to nitrocellulose membranes, incubated with
specific antibodies, and visualized by enhanced chemilumines-
cence (Tropix). Anti-KIT polyclonal antiserum (A4502; Dako
Cytomation) was diluted 1:500.
Blots were stripped and reprobed with a -actin antibody
(Sigma Chemical Co., Poole, United Kingdom) as a protein
loading control. KIT-containing complexes were immunopre-
cipitated in Ewing tumor cell lines from 300 g of protein
extracts with 1 g of antibody and 20 l of Protein A/G-plus-
Agarose (Santa Cruz Biotechnology Biotech). Immunoprecipi-
tates were washed five times with NET buffer. Samples then
underwent elution from Protein A/G, electrophoresis, and trans-
fer to nitrocellulose. Filters were incubated first with mouse
antiphosphotyrosine (Upstate Biotechnology). Nitrocellulose
filters were stripped of antibody using 0.5 M Tris-HCl (pH 6.8),
10% SDS, and 0.75% -mercaptoethanol at 65°C for 30 min
and then reprobed with polyclonal antibody anti-KIT (A4502;
Dako Cytomation).
Antibodies used to characterize phosphorylation status of
KIT signaling pathway were: phospho-p44/p42 MAPK (Thr202/
Tyr204) antibody (catalogue no. 9101), p44/42 MAPK antibody
(catalogue no. 9102), phospho-AKT (Ser473) antibody (cata-
logue no. 9271), and AKT antibody (catalogue no. 9270); all
antibodies were obtained from Cell Signaling Technology.
Immunohistochemistry. Formalin-fixed, paraffin-
embedded sections were incubated overnight at room tempera-
ture with polyclonal anti KIT antibody (A4502, dilution 1:100;
Dako Cytomation) and with phospho-KIT (Tyr719; polyclonal,
code 3391; dilution 1:50; Cell Signaling Technology, Inc., Bev-
erly, MA). Staining was performed with the EnVision system
(Dako Cytomation). Antigen retrieval using buffer citrate (pH
7.0), and microwave treatment for 20 min in an 800-W micro-
wave oven was performed. Sections of several GISTs were used
as controls. Results were evaluated by two independent observ-
ers (E. d. A. and A. P.) blinded to clinicopathological and mo-
lecular data. The number and intensity of immunoreactive cells
were evaluated in three randomly selected fields. The number
was expressed as the percentage of reactive cells. Intensity of
staining was scored  to  ( meant faint staining inten-
sity with incomplete membrane staining;  meant intense
and complete membrane staining). We considered immunore-
activity over 50% of cells as diffuse staining and intensity
as strong staining.
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Proliferation Assay. Three different assays were per-
formed in complete medium to mimic the effect of imatinib in
human tumors. First, dose response proliferation studies with
imatinib (0.5–20 M) were performed to assess the degree of
inhibition provoked by the drug. Cells (2000 cells/well) were
seeded in a 96-well cell culture and, after 48 h, were treated with
imatinib (0.5–20 M) for 24 h. To verify that KIT inhibition by
imatinib was not reverted by ligand stimulation, a second assay
was performed in which cells were treated under different
conditions as follows: imatinib (10 M) for 12 h; imatinib (10
Fig. 1 KIT/stem cell factor (SCF) expression in Ewing tumor cell lines, and KIT expression in clinical samples of Ewing tumors: A, reverse
transcription-PCR for c-kit. Expression of c-kit mRNA was found in all Ewing tumor cell lines studied. Bands at 106 and 118 bp, corresponding to
GNNK and GNNK isoforms, were found in all samples. B, Western blotting for KIT; a single band of 145 KDa was found in all cell lines. C,
reverse transcription-PCR for SCF. Expression of mRNA for SCF was found in all cell lines. A band at 409 bp (transmembrane isoform) was detected
with a consistent level of expression in all cell lines, except in A4573, which was almost negative; a band of 494 bp (soluble isoform) was found in
all Ewing tumor cell lines. D, immunohistochemical detection of KIT (see “Materials and Methods” for details) in SK-ES-1 cell line, showing
reactivity in the plasma membrane (300; inset, 1000). E, representative immunohistochemical analysis of KIT receptor in paraffin-embedded
tissue of a Ewing tumor. Note that reactivity shows a plasma membrane distribution; F represents detection of phosphorylated tyrosine at residue 719
of KIT receptor in the same sample. (400; inset, 1000).
Table 1 KIT expression and EWS-FLI1 transcript typea
Strong and
diffuse KIT
expression
TotalNo Yes
Transcript type
EWS-FLI1 type 1 18 4 22
EWS-FLI1 nontype 1 5 13 18
Total 23 17 40
a P 	 0.010 (Pearson’s 
2 test-Fisher’s exact test).
753Clinical Cancer Research
M) for 6 h and then combined with SCF (10 g/ml) for 6
additional h; and SCF (10 g/ml) alone for 6 h. A third assay
was performed to test if KIT inhibition would increase sensi-
tivity of these cells to chemotherapy. Cells were seeded as
described above and treated with varying concentrations of
DXR (range, 5–20 ng/ml) or VCR (range, 0.5–2.5 ng/ml) for
24 h with imatinib (range, 0.625–10 M) or without it (control).
Tritiated thymidine incorporation assay was used as a measure
of proliferation. Three replicate experiments were performed for
each cell line.
Apoptosis Studies. Apoptosis was measured after ima-
tinib treatment (10–20 M) for 12–72 h. To test cytotoxicity of
imatinib in combination with standard therapy, imatinib (10 M)
was administered with DXR and VCR at 0.25 g/ml and 5
ng/ml, respectively. The apoptotic index was assessed by flow
cytometry using Annexin-V-FITC kit (Bender Medsystems, Vi-
enna, Austria) following the manufacturer’s instructions. Data
acquisition and analysis were performed in a FACSort cytom-
eter (Becton Dickinson, Heidelberg, Germany) using CellQuest
Software (Becton Dickinson). For each analysis, 20,000 events
were acquired on a forward and side scatter gate. All experi-
ments were performed in complete medium.
Statistical Analysis. One-way ANOVA with HDS
Tukey’s test was used to detect differences in proliferation
among groups. Pearson’s 
2 test-Fisher’s exact test were used to
compare expression levels of KIT in patient samples with re-
spect to EWS-FLI1 transcript type.
RESULTS
KIT Signaling Pathway Activation in Ewing Tumors Is
Functional and Is Not Associated with Receptor Mutations.
All Ewing tumor-derived cell lines expressed mRNA of the two
alternative spliced forms of c-kit (Fig. 1A). Sequencing of both
Fig. 2 Functionality of KIT receptor. Immunoprecipitation studies were performed in all cell lines under different conditions, including SCF
stimulation during 1 and 5 min, with and without imatinib (10 M). Filters were incubated first with mouse antiphosphotyrosine (top gels) to assess
the degree of phosphorylation of the receptor. All cell lines showed basal KIT phosphorylation level in FBS-free conditions showing a functional
autocrine loop KIT/stem cell factor (SCF) (Lane 1, FBS ). Receptor was also active in presence of FBS (Lane 2, FBS ). Receptor phosphorylation
increased after incubation with exogenous SCF after a 1-min treatment (Lane 3, SCF 1 min) or a 5-min treatment (Lane 5; SCF 5 min).
Phosphorylation was higher after 5-min treatment (Lane 5). Imatinib treatment (10 M) provoked a decrease of SCF-induced KIT phosphorylation
in all cell lines. Kinase activity of the receptor was markedly inhibited by imatinib pretreatment. (Lane 4, 10 M imatinib/SCF 1 min, and Lane 6,
10 M imatinib/SCF 5 min). Filters were then stripped and reprobed with polyclonal antibody anti KIT (bottom gels) to control for lane load. Bands
of similar intensity confirmed that equal amounts of protein were loaded in each experimental sample. IP, immunoprecipitation; WB, Western blotting.
Fig. 3 Extracellular signal-regulated kinase (ERK) 1/2 signaling path-
way activation. A, top blot, ERK 1/2 time course activation after stem
cell factor (SCF) stimulation. ERK signaling pathway was specifically
induced by SCF. In A673 cell line, p-ERK 1/2 was detected after 5 and
15 min of stimulation (Lanes 2 and 3, respectively). The maximal
activity induction was found after 15 min of SCF stimulation (Lane 3).
ERK 1/2 phosphorylation was undetectable at longer time exposures
(Lane 4, 30 min; Lane 5, 1 h; Lane 6, 2 h, and Lane 7, 3 h). Lanes 1 and
8 correspond to controls included in the experiment as follows: Lane 1,
ERK 1/2 activity at 0.4% FBS concentration, and Lane 8, ERK 1/2
activation at complete medium (FBS 20%). Bottom blot: total ERK 1/2
protein. No changes in protein expression were found after SCF stim-
ulation. Total ERK 1/2 expression and -actin were used to control for
protein loading. B, top blot: p-ERK 1/2 detection in Ewing tumor
clinical samples (Lanes 1–4). All cases presented strong mitogen-
activated protein kinase signaling activation. Bottom blot: total ERK 1/2
protein detection in Ewing tumor clinical samples. Total ERK 1/2
expression and -actin were used to control for protein loading.
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bands confirmed GNNK and GNNK isoforms. c-kit expres-
sion was also found by reverse transcription-PCR in clinical
samples (data not shown). Sequencing of the coding region of
c-kit also showed a previously reported isoform lacking three
nucleotides, 2164 A, 2165 G, and 2166 C, corresponding to a
codon in the mid-segment of the split-kinase domain (exon 15),
encoding serine in position 715. Expression of KIT was also
demonstrated at the protein level (Western blot and immuno-
histochemistry) in all four cell lines (Fig. 1, B and D, respec-
tively). mRNA from both SCF isoforms, soluble (including
exon 6) and transmembrane (lacking exon 6), were expressed in
all cell lines (Fig. 1C). Sequencing of PCR fragments revealed
germ-line SCF. To demonstrate the expression of KIT receptor
in Ewing tumor biopsy material, we performed immunohisto-
chemistry in 110 samples. In 49 of them, strong and diffuse
staining was seen including the plasma membrane and/or the
cytoplasm (Fig. 1E), whereas in 41 samples, staining showed a
weak nuclear pattern. Scattered mast cells, immunoreactive with
KIT, were found in several samples and were useful as a
positive internal control; all GISTs showed strong and diffuse
staining. There was no relationship of KIT staining with gender,
age, metastasis at diagnosis, and tumor location. EWS-FLI1
fusions were found in 40 patients (in 22 were type 1, and 18 had
nontype 1), and EWS-ERG in 2 patients. The samples showing
EWS-FLI-1 nontype 1 fusions had strong and diffuse staining
for KIT more frequently than those having EWS-FLI1 type 1
transcripts (Table 1; P 	 0.01 Pearson’s 
2 test-Fisher’s exact
test).
Ewing tumor cell lines and clinical samples showed SCF/
KIT pathway phosphorylation. As shown in Fig. 2, all cell lines
presented a basal level of KIT phosphorylation either in medium
supplemented with fetal bovine serum or in serum-free medium
(supplemented with insulin, transferrin, and selenium). Receptor
phosphorylation increased in all cell lines after treatment with
exogenous SCF (Fig. 2). KIT activation was rapidly induced
after 1- or 5-min SCF stimulation. Accordingly, 11 Ewing tumor
samples showed immunoreactivity for phospho-KIT (Tyr719;
Fig. 1F) decorating the plasma membrane; mast cells, immuno-
reactive for Phospho-KIT, served as internal control; all GISTs
were negative. Phospho-KIT (Tyr719) antibody specificity was
evaluated on three frozen clinical samples of Ewing tumor. Cell
lysates were immunoprecipitated with a polyclonal KIT anti-
body, and Western blotting analysis was then performed using
phospho-KIT (Tyr719) antibody, followed by total KIT detec-
tion. All of them showed a 145-KDa band after Western blot-
ting, indicating KIT phosphorylation in Tyr719 residue (data not
shown).
Moreover, members of the MAPK signaling pathway, ex-
tracellular signal-regulated kinase (ERK)1 and ERK2, showed
activation between 5 and 15 min after SCF stimulation (Fig.
3A). Analogously, p-ERK1/2 was detected (Fig. 3B) in all four
primary Ewing tumors.
Sequencing results of c-kit revealed absence of mutations
in Ewing tumor cell lines and clinical samples. These results
show that in Ewing tumor cell lines and clinical samples SCF/
KIT pathway is active, despite the absence of activating muta-
tions of c-kit.
Imatinib-Mediated Inhibition of KIT Receptor Pre-
vents Ewing Tumor Cell Proliferation but Does Not Induce
Significant Apoptosis at Clinically Relevant Doses. To as-
sess if SCF-KIT pathway participates in proliferation of Ewing
tumor cells and whether imatinib may have a role in the treat-
ment of patients with Ewing tumor, we analyzed KIT activity
and the proliferative rate of Ewing tumor cell lines after expo-
sure to imatinib. As shown in Fig. 2, imatinib (10 M) treatment
caused an irreversible decrease of spontaneous and SCF-
Fig. 4 Inhibition of KIT kinase activity after imatinib treatment. Ima-
tinib treatment provoked a marked inhibition in receptor phosphoryla-
tion in a dose-dependent manner. This figure shows phosphorylation
status of KIT with different concentrations of imatinib (0, 0.1, 0.5, 1,
and 10 M) in presence of stem cell factor. IC50 for KIT kinase activity
was 0.5–1 M. At 10 M imatinib, receptor activity was completely
blocked. IP, immunoprecipitation; WB, Western blotting.
Fig. 5 Imatinib mediated inhibition of signal transduction pathway
triggered by KIT. A, Top blot: stem cell factor (SCF)-induced extracel-
lular signal-regulated kinase (ERK) 1/2 phosphorylation was partially
inhibited with imatinib pretreatment in A673 cell line. After 5 and 15
min of SCF treatment (Lanes 2 and 4, respectively), signaling pathway
triggered by KIT was activated, showing p-ERK 1/2 phosphorylation.
However, imatinib pretreatment was able to block the signaling cascade
carried out by KIT as shown by the decrease in ERK 1/2 phosphoryl-
ation (Lanes 3 and 5): Lane 3, 10 M imatinib/SCF (5 min), and Lane
5, 10 M imatinib/SCF (15 min). Lane 1: ERK 1/2 activity at 0.4% FBS
concentration. Bottom blot: total ERK 1/2 protein; no changes in protein
expression were found after SCF stimulation. Total ERK 1/2 expression
and -actin were used to control for protein loading. B, Top blot: p-AKT
detection after imatinib treatment in A673. No changes in AKT phos-
phorylation levels were found after imatinib treatment. Lane 1, FBS;
Lanes 2–4, 10 M imatinib for 12, 24, and 48 h, respectively; and Lanes
5–7, 20 M imatinib for 12, 24, and 48 h, respectively. Experiments
were performed in complete medium. Bottom blot: total AKT protein;
no changes in protein expression were found after imatinib treatment.
Equal amounts of protein were loaded.
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induced KIT phosphorylation. Nevertheless, KIT activity inhi-
bition was found at doses  10 M. In fact, IC50 for KIT kinase
activity inhibition was 1 M imatinib (Fig. 4). Analogously,
phosphorylation of ERK1/2, a downstream target of KIT sig-
naling pathway, was also partially inhibited by imatinib (Fig.
5A), indicating that this drug effectively inhibits signal trans-
duction triggered by KIT in Ewing tumor cell lines.
In addition, treatment with imatinib provoked a marked
decrease in DNA synthesis after a 24- and 48-h treatment, which
was dose dependent (Fig. 6). IC50 for cellular proliferation
ranged between 12 and 15 M.
The number of early apoptotic cells (Annexin-V , pro-
pidium iodide ) did not show any significant increase in any
cell line after 10 M imatinib treatment. Nevertheless, we found
a mild increase (12%) in Annexin V-positive cells after treat-
ment of two cell lines, A673 and SK-ES-1, with higher imatinib
concentrations (20 M; data not shown). Accordingly, as shown
in Fig. 5B, imatinib alone (10 or 20 M for 12, 24, and 48 h)
failed to inhibit constitutively AKT kinase, a crucial molecule in
Ewing tumor cell survival modulation.
Increased Cytotoxicity of Combined in Vitro Treat-
ments. We then investigated whether KIT kinase activity in-
hibition might increase cell susceptibility to chemotherapeutic
drugs usually used for Ewing tumor treatment such as DXR and
VCR. As shown in Figs. 7 and 8, the combined treatment with
increasing concentrations of Imatinib (0.625–10 M) and DXR
or VCR (dose ranging 5–20 ng/ml and 0.5–2.5 ng/ml, respec-
tively, depending on the particular sensitivity of the cell line to
the drug) resulted in a higher growth inhibition in all cell lines
than the observed with DXR or VCR alone. Cotreatment with
DXR and imatinib resulted in a 15–20% increase of antiprolif-
erative effect with respect to the therapeutic efficacy of chem-
otherapy alone. Similar results were obtained with combinations
of VCR and imatinib, which showed an increased toxicity of
15–36%. Maximal inhibition was obtained using 10 M ima-
tinib.
Imatinib, given at the same concentration that was unable
to induce apoptosis when administered alone (10 M), enhanced
toxicity caused by both chemotherapeutic agents in combined
treatments (Figs. 9 and 10). Imatinib, combined with DXR (25
g/ml) or VCR (5 ng/ml) in A673 cell line, increased in 15%
Fig. 6 Growth inhibition mediated
by imatinib dose response analysis
of imatinib in Ewing tumor cell
lines. Cells at a density of 2000
cells/well were seeded in a 96-well
cell culture plate in culture medium
with FBS and then treated with ima-
tinib (0.625–20 M) for 24 h. A
marked decrease in thymidine incor-
poration was found in all Ewing tu-
mor cell lines after imatinib. Growth
inhibition was dose dependent, be-
ing more pronounced over 10 M
imatinib. IC50 for cell proliferation
ranged between 12 and 15 M.
Fig. 7 Additive cytotoxicity of doxorubicin (DXR) in combination
with imatinib on Ewing tumor cell lines. Combined treatment of ima-
tinib with DXR resulted in a decrease of the proliferative rate of Ewing
tumor cells with respect to controls (imatinib or DXR alone). Cells were
treated with DXR alone (F; 5–20 ng/ml, depending on the sensitivity of
cell line), imatinib alone () at the mentioned concentrations, and with
both drugs simultaneously for 24 h (Œ). Drug combination resulted in a
decrease of between 15–20% in thymidine incorporation with respect to
DXR alone. Maximal effect in combined treatments was found at 10 M
imatinib. Three replicate experiments were performed for each cell line.
A representative experiment is shown in the figure.
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(imatinib  DXR) or 30% (imatinib  VCR) cellular apoptosis
with respect to controls (DXR or VCR alone), showing that
inhibition of the receptor pathway sensitized cells to conven-
tional cytotoxic drugs, improving the antitumor activity of DXR
and VCR.
DISCUSSION
As a first step to assess whether KIT is a potential thera-
peutic target in Ewing tumor, we confirmed that SCF/KIT
autocrine loop components (35–39) are expressed in Ewing
tumor cell lines and clinical samples (25–27). In the present
study, all KIT isoforms were found to show a consistent level of
expression in all cell lines (36, 40, 41). Furthermore, almost half
of clinical samples of Ewing tumor showed KIT immunoreac-
tivity with membrane/cytoplasmic patterns. This to our knowl-
edge is the largest series reported thus far of clinical samples of
Ewing tumor in which KIT expression has been assessed by
immunohistochemistry. Reported incidence of KIT reactivity in
Ewing tumor biopsy specimens ranges between 29 and 71% (25,
42), depending on the technical conditions used in the study.
Interestingly, we found that tumors having the most common
type of EWS-FLI1 fusion transcript, type 1, had a lower degree
of KIT expression than tumors having other fusion types. This
particular fusion type is associated with a favorable prognosis
(33) and to a lower expression of insulin-like growth factor I
receptor (43), another membrane receptor relevant to Ewing
tumor survival pathways. Our results could represent an addi-
tional biological basis for the relatively good prognosis of
patients having EWS-FLI1 type 1 fusions.
KIT expression, however, does not necessarily equate with
a functional and active receptor. We did not find any mutations
in the whole coding region of c-kit of any of the cell lines and
clinical samples studied. Importantly, despite the absence of
mutations in the coding region of c-kit, our immunoprecipitation
experiments showed that KIT is a functional receptor in Ewing
tumor cell lines. A basal phosphorylation level was found in all
cell lines in presence of FBS as well as in serum-free medium,
suggesting a functional autocrine loop SCF/KIT. Furthermore,
all cell lines showed a marked KIT phosphorylation increase in
presence of exogenous SCF, indicating that the signaling path-
way is functional. Accordingly, a subset of formalin-fixed,
paraffin-embedded biopsies showed expression of phosphoryl-
ated KIT in the residue Tyr719. Active ERK 1/2 was also
detected by Western blotting in the same clinical samples. These
results demonstrate that SCF/KIT/ERK 1/2 pathway is active in
a subset of Ewing tumors.
Additional evidence that Ewing tumor cell lines are de-
pendent on KIT activation for proliferation is given by the
marked decrease in KIT and MAPK phosphorylation levels after
treating cells with imatinib, as evaluated by immunoprecipita-
Fig. 8 Additive cytotoxicity of vincristine (VCR) in combination with imatinib on Ewing tumor cell lines. Thymidine incorporation assays showed
again a higher cytotoxicity in combined treatments (VCR  imatinib) with respect to controls (VCR or imatinib alone). Cells were treated with VCR
alone (E; 5–20 ng/ml, depending on the sensitivity of cell line), imatinib alone () at the mentioned concentrations, and with both drugs
simultaneously for 24 h (Œ). Drug combination resulted in a decrease of between 20–36% in thymidine incorporation with respect to VCR alone.
Maximal effect in combined treatments was found at 10 M imatinib. Three replicate experiments were performed for each cell line. A representative
experiment is shown in the figure.
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tion and Western blotting. These experiments show that the drug
was able to block KIT signaling pathway activation. Moreover,
proliferation assays with imatinib treatment revealed a dose-
dependent decrease in in vitro thymidine incorporation in all cell
lines, indicating that KIT provides an important signal for pro-
liferation in Ewing tumor cell lines. A previous study by Hot-
filder et al. (44) suggested that imatinib had a low and transitory
effect on the growth proliferation of several Ewing tumor cells.
It is worth mentioning that this group demonstrated KIT recep-
tor expression although did not assess its functionality. More-
over, Hotfilder et al. (45) obtained cell growth inhibition only at
high doses of imatinib, which have been reported to be unspe-
cific. Therefore, the possibility of the drug acting through other
pathways should be considered in this particular case.
Our assays were designed to investigate the activity of
imatinib in cell line models at levels similar to the approximate
plasma concentrations resulting from standard dose regimen of
imatinib. Therefore, combined treatments were carried out with
10 M imatinib because higher concentrations are above those
maximally tolerated in Phase I clinical trials (close to 1000
mg/day, which correspond to 6–10 M in blood levels; Ref. 46).
For example, a mean maximal concentration of 4.6 M was
reached at steady state by once-daily administration of 400 mg
of imatinib in patients with chronic myelogenous leukemia (29).
Fig. 9 Increased apoptotic levels after combined treatment with DXR and imatinib. A–D represent significant flow cytometry experiments analyzing
Annexin-V-FITC detection. Histograms showing Annexin-V and propidium iodide distribution in presence of FBS (A), 10 M imatinib (B), and
imatinib with doxorubicin (DXR; C) are shown in the top half of the figure. The number of A673 early apoptotic cells (Annexin-V , propidium
iodide ) increased when combined treatment was administered (48%) with respect to DXR alone (33%). D shows curve displacement of imatinib
 DXR with respect to DXR alone.
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Phase III clinical trials of adjuvant imatinib versus placebo in
patients after the complete resection of primary GIST use doses
of up to 800 mg/day. Besides, it is known that imatinib loses
some specificity at concentrations  10 M (45). Therefore,
higher concentrations of the drug induce proliferation arrest and
apoptosis probably by inhibition of other tyrosine kinases. De-
spite consistent inhibition of cell proliferation, imatinib alone
was not able to induce a significant degree of apoptosis in
Ewing tumor cell lines at clinically relevant concentrations (10
M). Other authors have found an induction of apoptosis after
imatinib treatment in in vitro experiments performed with lower
concentrations of FBS and higher concentrations of the drug (20
M; Ref. 27). We confirmed these results but used a broader
drug concentration range (2–20 M) in a broader time range to
determine whether in presence of FBS, a rich growth factor
microenvironment, imatinib was able to induce cell death. The
SCF/KIT pathway has been shown to protect tumor cells from
apoptosis by sequential activation of phosphatidylinositol 3-
kinase, AKT, and BAD (47). AKT promotes cell survival and
plays a critical role in controlling balance between survival and
apoptosis. The absence of a significant increase of apoptosis
after treatment with imatinib represents, in turn, evidence that
other pathways, as for example insulin-like growth factor I
receptor/phosphatidylinositol 3-kinase/AKT, might be more
relevant to Ewing tumor cell survival (48). Accordingly, our
experiments showed no differences in expression and phospho-
rylation status of AKT in any Ewing tumor cell line after
imatinib treatment. This is analogous to the results reported in
Fig. 10 Increased apoptotic levels after combined treatment with vincristine (VCR) and imatinib. A–D represent significant flow cytometry
experiments analyzing Annexin-V-FITC detection. Histograms showing Annexin-V and propidium iodide distribution in presence of FBS (A), 10 M
imatinib (B), and imatinib with VCR (C) are shown in the top half of the figure. The number of A673 early apoptotic cells (Annexin-V , propidium
iodide ) increases when combined treatment was administered (50%) with respect to VCR alone (20%). D shows curve displacement of imatinib
 VCR with respect to VCR alone.
759Clinical Cancer Research
small cell lung cancer, another solid tumor with KIT expression,
in which imatinib is cytostatic and unable to induce apoptosis
(49) Conversely, imatinib induces both AKT activity blockade
in BCR-ABL-positive cells together with relevant levels of
apoptosis (50).
One key finding of this study is that combination of ima-
tinib with conventional drugs in Ewing tumor treatment such as
DXR and VCR substantially improves their cytotoxic effect.
The agents we used for the combination with imatinib were
selected because they are included in nearly all conventional
chemotherapeutic protocols for Ewing tumor (51). Although
data suggest that KIT is not critical for Ewing tumor cell
survival, blockade of the receptor made cells more susceptible to
cellular damage caused by cytotoxic drugs. This effect suggests
that KIT signaling pathway blockade with imatinib is not com-
pletely rescued by other growth factor signaling pathways. This
is to our knowledge the first study showing benefit of combi-
nation therapy with imatinib and VCR and DXR in a solid tumor
without mutations of the c-kit gene. This is, for example, in
contrast to what is observed in small cell lung cancer in which
high imatinib concentrations have a cytostatic effect, and com-
bination with carboplatinum or etoposide does not trigger apo-
ptosis (49)
The metastatic sites associated to the worst prognosis in
Ewing tumor are the bone and bone marrow, two SCF-rich
tissues (52). Interestingly, in a recent study (26), Ewing tumor
cells injected i.v. into athymic nude mice metastasized to a
variety of SCF-rich microenvironments. Metastatic cells that
find an SCF-rich microenvironment may present a proliferative
advantage with respect to other locations with lower concentra-
tions of growth factors. Therefore, the use of imatinib in Ewing
tumor metastatic to bone marrow or bone could be of high
therapeutic interest because treatment of Ewing tumor cell lines
with imatinib results in a strong inhibition in the proliferative
rate that does not revert in the presence of high concentrations
of exogenous SCF.
Taken together, our results demonstrate that inhibition of
Ewing tumor cell proliferation by imatinib is mediated through
inhibition of KIT receptor signaling and that inhibition of KIT
increases sensitivity of these cells to DXR and VCR. The data
suggest that clinical trials using imatinib for refractory or met-
astatic KIT-expressing Ewing tumor in combination with other
chemotherapeutic agents may be warranted based upon these
observations.
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